A center to manage and coordinate cancer therapy resistance data
Official title: Coordinating and Data Management Center for Acquired Resistance to Therapy Network
Funded at Roswell Park Cancer Institute Corp · NIH-11257819 · Data updated 2026-11-12
This study is working on a new center to help cancer researchers share and manage information about why some treatments stop working, so they can come up with better ways to fight cancer together.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $74,605 |
| NIH project number | 3U24CA274159-03S2 |
| Project ID | NIH-11257819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing cancer treatment who may experience resistance to therapies.
✕Less likely to help
Patients who are not currently receiving cancer treatment or those with conditions unrelated to cancer therapy resistance may not benefit from this research.
What this research studies
This research focuses on creating a Coordinating and Data Management Center that will support the Acquired Resistance to Therapy Network (ARTNet). It aims to manage and integrate data related to cancer therapy resistance, facilitating collaboration among researchers. By providing a centralized infrastructure and promoting community engagement, the center will enhance the productivity of ARTNet investigators and improve access to analytical expertise. The ultimate goal is to develop new strategies to overcome challenges in cancer treatment resistance.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for overcoming resistance to cancer therapies, potentially enhancing treatment outcomes for patients.
How similar studies have gone: Previous research initiatives focused on cancer therapy resistance have shown promise, indicating that collaborative approaches can yield significant advancements in treatment strategies.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Hutson, Alan David — Roswell Park Cancer Institute Corp
- Study coordinator: Hutson, Alan David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.